Cabaletta Bio (CABA) EBT (2018 - 2025)
Cabaletta Bio's quarterly EBT came in at -$41.8 million in Q4 2025, down 28.4% year-on-year from -$58.4 million in Q4 2024, and up 7.77% quarter-over-quarter from -$45.4 million in Q3 2025.
Cabaletta Bio has reported EBT for 8 years, with the latest figure at -$41.8 million in Q4 2025.
- For the quarter ending Q4 2025, EBT fell 28.4% year-over-year to -$41.8 million; the trailing twelve-month figure through Dec 2025 stood at -$168.2 million (down 45.18% YoY), and the FY2025 full-year result was -$168.2 million, down 45.18% from the prior year.
- EBT for Q4 2025 stood at -$41.8 million, up from -$45.4 million in the prior quarter.
- The five-year high for EBT was -$9.7 million in Q1 2021, with the low at -$45.4 million in Q3 2025.
- Average EBT over 5 years is -$22.6 million, with a median of -$16.2 million recorded in 2023.
- Year-over-year, EBT increased 1.15% in 2022 and tumbled 90.53% in 2024.
- Tracing CABA's EBT over 5 years: stood at -$13.9 million in 2021, then retreated by 12.99% to -$15.7 million in 2022, then slumped by 33.1% to -$20.9 million in 2023, then slumped by 56.02% to -$32.6 million in 2024, then retreated by 28.4% to -$41.8 million in 2025.
- The last three EBT figures came in at -$41.8 million (Q4 2025), -$45.4 million (Q3 2025), and -$45.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Cabaletta Bio | 194.84 Mn | 61.24 Mn | - | -41.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -41.84 Mn |
| Sep 30, 2025 | -45.36 Mn |
| Jun 30, 2025 | -45.07 Mn |
| Mar 31, 2025 | -35.94 Mn |
| Dec 31, 2024 | -32.59 Mn |
| Sep 30, 2024 | -30.63 Mn |
| Jun 30, 2024 | -27.60 Mn |
| Mar 31, 2024 | -25.05 Mn |
| Dec 31, 2023 | -20.89 Mn |
| Sep 30, 2023 | -16.45 Mn |
| Jun 30, 2023 | -14.49 Mn |
| Mar 31, 2023 | -15.85 Mn |
| Dec 31, 2022 | -15.69 Mn |
| Sep 30, 2022 | -11.43 Mn |
| Jun 30, 2022 | -12.91 Mn |
| Mar 31, 2022 | -12.95 Mn |
| Dec 31, 2021 | -13.89 Mn |
| Sep 30, 2021 | -11.56 Mn |
| Jun 30, 2021 | -11.14 Mn |
| Mar 31, 2021 | -9.70 Mn |
| Dec 31, 2020 | -9.31 Mn |
| Sep 30, 2020 | -8.39 Mn |
| Jun 30, 2020 | -8.15 Mn |
| Mar 31, 2020 | -7.49 Mn |
| Dec 31, 2019 | -5.40 Mn |
| Sep 30, 2019 | -4.65 Mn |
| Jun 30, 2019 | -3.36 Mn |
| Mar 31, 2019 | -3.53 Mn |
| Dec 31, 2018 | -1.91 Mn |
| Sep 30, 2018 | -3.03 Mn |